The Effect of Vicia Faba Hydrolysate Supplementation on Muscle Strength Recovery
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-45
SponsorPepsiCo Global R&D
About this trial
To investigate the effect of Vicia faba protein concentrate, a protein derived from Fava bean extract, on delayed onset muscle soreness (DOMS). Participants receive either 2.4g/day of PeptiStrong® supplement capsules or placebo capsules for 14 days until a strenuous exercise session. For the last 3 days, 2/3 of them stay on the same treatment and 1/3 of them switch from placebo to PeptiStrong®.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Males and females 18 - 45 years of age.
Willing to fast overnight on the 4 testing occasions.
Participants agree to abstain from taking additional supplements throughout the testing period, with particular emphasis placed upon protein-based products (e.g., whey or casein based protein powders; animal derived protein hydrolysates; natural supplements constituted of vegetative protein hydrolysates from rice, fava bean, pea, carrot, spirulina, broccoli, potatoes; marine derived secondary metabolite products or protein hydrolysates including Omega-3 capsules or DHA).
Moderately active (exercise 3-5 days per week)
Disqualifiers
Individuals that are glucose-6-phosphate-dehydrogenase deficient. The test product in this study contains fava bean extract which may produce favism in genetically susceptible individuals.
Alcohol or drug abuse in the past year.3. Testosterone or estrogen supplementation (not including women on oral contraceptives)
Pregnant or nursing or planning to become pregnant.
Participation in any other clinical trial in the past 30 days. Participation in any PepsiCo trial in the past 6 months
Trial design
Design model
Crossover
Treatments tested in this trial
Placebo control capsules
Other intervention2.4 grams (g) daily
PeptiStrong® supplement capsules with same appearance as placebo capsules
Other intervention2.4 g daily
PeptiStrong® supplement capsules following muscle damaging exercise on Day 14
Other intervention2.4 g placebo capsules for 14 days, then 3 days 2.4 g of PeptiStrong® capsules following one muscle damaging exercise session
Treatment groups
76 Participants
are divided into 3 treatment groupsGroup A: PlaceboPlacebo comparator 1 intervention
Group B: PeptiStrong® 17 daysExperimental treatment 1 intervention
Group C: PeptiStrong® 3 daysExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Concentric knee extension and flexion strength
Assessed at an angular velocity of 60°/s through the range of 0-100° knee flexion using an isokinetic dynamometer (Biodex)
Time frame
Following strenuous muscle damaging exercise on Day 14Secondary outcomes
1
Exercise induced expression of markers of muscle stress
Plasma concentrations of IL-6, IL-15, fractalkine, irisin, FGF21, myostatin, osteocrin / PEP- 2414 Page 9 of 32 1/29/25 V6 musclin, osteonectin/SPARC
Time frame
Days 14 at Baseline and 2 hrs post strenuous exercise, and on Days 16 and 17 at 10 minutes post exercise2
Ratings of soreness, fatigue, pain, and tenderness.
Rated on a 4-item Recovery survey, anchored from none to extreme
Time frame
Days 14, 15, 16, 17 based on the previous 24 hours3
Fatigue index
Calculated from the strength tests using the following equation: (highest force - lowest force) / highest force
Time frame
Baseline Day 0, Day 16 and Day 17 for each strength testSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov